Trial Profile
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Oct 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms ALAIN01
- 25 Oct 2021 Status changed from recruiting to completed.
- 20 Jan 2021 This trial has been completed (Global End Date: 02 Nov 2020), according to European Clinical Trials Database record.
- 17 Jun 2016 Planned End Date changed from 1 Sep 2019 to 1 May 2020.